Extrusion process for forming chemically stable drug multiparticulates
View Patent ↗Reduced levels of drug degradation in drug-containing multiparticulates are obtained by an extrusion/melt-congeal process.
1. A process for the formation of chemically stable drug-containing multiparticulates comprising:
(a) forming in an extruder a molten mixture comprising a labile drug and a pharmaceutically acceptable carrier, wherein said carrier is selected from the group consisting of waxes, long-chain alcohols, long-chain fatty acid esters, and mixtures thereof, wherein said drug in said molten mixture is at least 70 wt % crystalline;
(b) delivering said molten mixture to an atomizing means to form droplets of said molten mixture; and
(c) congealing said droplets to form multiparticulates.
2. The process of claim 1 wherein the mean time said drug is present in said molten mixture is greater than 5 seconds but less than or equal to 20 minutes.
3. The process of claim 2 wherein the mean time said drug is present in said molten mixture is greater than 10 seconds but less than or equal to 15 minutes.
4. The process of claim 3 wherein the mean time said drug is present in said molten mixture is greater than 10 seconds but less than or equal to 10 minutes.
5. The process of claim 1 wherein said extruder is selected from the group consisting of single-screw extruders, twin-screw extruders, multiple screw extruders, ram extruders, gear-pump extruders, and conveyer extruders.
6. The process of claim 1 wherein said atomizing means is selected from the group consisting of spinning disk atomizers, pressure nozzles, single-fluid nozzles, two-fluid nozzles, ultrasonic nozzles, and mechanical vibrating nozzles.
7. The process of claim 6 wherein said atomizing means is a spinning disk atomizer.
8. The process of claim 1 wherein said carrier is selected from the group consisting of synthetic wax, microcrystalline wax, paraffin wax, Carnauba wax, white and yellow beeswax, stearyl alcohol, cetyl alcohol, polyethylene glycol, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated vegetable oils, mono-, di-, and trialkyl glycerides, glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, glyceryl tristearate, glyceryl tripalmitate, and mixtures thereof.
9. The process of claim 1 wherein said molten mixture further includes a dissolution enhancer.
10. The process of claim 9 wherein said dissolution enhancer is selected from the group consisting of a alcohols, surfactants, sugars, salts, amino acids, and mixtures thereof.
11. The process of claim 10 wherein said dissolution enhancer is selected from the group consisting of stearyl alcohol, cetyl alcohol, polyethylene glycol poloxamers, docusate salts, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polysorbates, polyoxyethylene alkyl esters, sodium lauryl sulfate, sorbitan monoesters, glucose, sucrose, xylitol, sorbitol, maltitol, sodium chloride, potassium chloride, lithium chloride, calcium chloride, magnesium chloride, sodium sulfate, potassium sulfate, sodium carbonate, magnesium sulfate, potassium phosphate, alanine, glycine, and mixtures thereof.
12. The process of claim 11 wherein said carrier is a mixture of glyceryl mono-, di- and tribehenates and said dissolution enhancer is a poloxamer.
13. The process of claim 1 wherein said drug is selected from the group consisting of antihypertensives, antianxiety agents, anticlotting agents, anticonvulsants, blood glucose-lowering agents, decongestants, antihistamines, antitussives, antineoplastics, beta blockers, anti-inflammatories, antipsychotic agents, cognitive enhancers, anti-atherosclerotic agents, cholesterol-reducing agents, antiobesity agents, autoimmune disorder agents, anti-impotence agents, antibacterial and antifungal agents, hypnotic agents, anti-Parkinsonism agents, anti-Alzheimer's disease agents, antibiotics, anti-depressants, antiviral agents, glycogen phosphorylase inhibitors. and cholesterol ester transfer protein inhibitors.
14. The process of claim 1 wherein said multiparticulates exhibit a relative degree of improvement in drug degradation of at least 1.05.
15. The process of claim 14 wherein said relative degree of improvement in drug degradation is at least 1.10.
16. The process of claim 15 wherein said relative degree of improvement in drug degradation is at least 1.25.
17. The process of claim 16 wherein said relative degree of improvement in drug degradation is at least 2.
18. The process of claim 17 wherein said relative degree of improvement in drug degradation is at least 5.
19. The process of claim 18 wherein said relative degree of improvement in drug degradation is at least 10.